Short Interest in Nascent Biotech, Inc. (OTCMKTS:NBIO) Rises By 16,400.0%

Nascent Biotech, Inc. (OTCMKTS:NBIO) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 16,500 shares, a growth of 16,400.0% from the December 31st total of 100 shares. Based on an average daily volume of 293,000 shares, the short-interest ratio is currently 0.1 days.

Nascent Biotech Stock Performance

Shares of NBIO stock remained flat at $0.00 during trading hours on Friday. The firm’s 50-day moving average is $0.04 and its two-hundred day moving average is $0.05. Nascent Biotech has a fifty-two week low of $0.00 and a fifty-two week high of $0.19.

About Nascent Biotech

Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.